Cadence Pharmaceuticals Reports First Quarter 2007 Financial Results and Development Highlights

SAN DIEGO, May 14 /PRNewswire-FirstCall/ -- Cadence Pharmaceuticals, Inc. (NASDAQ: CADX) , a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting, announced today unaudited financial results for the first quarter ended March 31, 2007. Cadence reported a net loss for the first quarter of 2007 of $9.6 million, or $0.34 per share, compared to a net loss of $29.2 million, or $23.84 per share, in the first quarter of 2006.

As of March 31, 2007, Cadence held cash and cash equivalents of $77.4 million.

"We continue to make steady progress with our Phase III development programs for our two product candidates, IV APAP for the treatment of acute pain and fever in both adults and children, and Omigard(TM) for the prevention of catheter-related infections. Our product candidates are intended to address major issues that patients and hospitals face everyday, including controlling pain and reducing infections," said Ted Schroeder, President and Chief Executive Officer of Cadence. "In the coming months, we plan to continue to advance the enrollment of these two clinical programs and anticipate that we will fully enroll all of our planned clinical trials of IV APAP for the treatment of acute pain and fever by the end of this year."

Financial Results

Total operating expenses for the first quarter of 2007 were $10.4 million, compared to $29.4 million for the first quarter of 2006. The $19.0 million decrease in operating expenses in the first quarter of 2007 was primarily due to the $25.3 million initial license fee for IV APAP that Cadence incurred during the first quarter of 2006. This decrease was partially offset by increased costs during the first quarter of 2007 related to the company's ongoing Phase III clinical trial of Omigard, its Phase III clinical trial of IV APAP, which began enrollment in December 2006, and the hiring of additional research and development staff to support its clinical and regulatory efforts. In addition, general and administrative expenses increased by $1.3 million as a result of stock-based compensation expenses and other personnel-related costs, costs related to operating as a public company, and costs related to a new corporate facility.

  Recent Highlights and Developments
  *  Cadence recently appointed two new important members to its management
     team. Hazel M. Aker, J.D., joined the company as Senior Vice President,
     General Counsel and Corporate Secretary, and Catherine J. Hardalo, M.D.
     joined the company as Vice President, Clinical Development.  Ms. Aker
     is responsible for overseeing legal affairs and has previously held
     positions at Ambrx, Inc., and Micromet, Inc. (formerly CancerVax
     Corporation), where she served as General Counsel, among other roles.
     Dr. Hardalo will direct the company's anti-infective program and joins
     Cadence from Schering-Plough Corporation, where she was most recently
     Senior Director, Infectious Diseases and Dermatology Global Clinical
     Development.
  *  In April 2007, Cadence presented data from an adult pharmacokinetic
     study that demonstrated that IV APAP has comparable pharmacokinetics
     and pharmcodynamics to oral acetaminophen.  In addition, the study
     showed that IV APAP appeared to be well tolerated with a side effect
     profile similar to oral acetaminophen.   The study, presented at the
     American Society of Regional Anesthesia and Pain Medicine's 32nd Annual
     Meeting held in Vancouver, British Columbia, was a randomized, four-
     period, crossover trial that enrolled 32 healthy adult men.
  *  Also in April 2007, Cadence announced that it plans to discuss with the
     U.S. Food and Drug Administration (FDA) a proposal to increase the
     number of patients to be enrolled in its ongoing Phase III clinical
     trial of Omigard in order to maintain the statistical power of the
     trial. The modification of this clinical trial was prompted by
     Cadence's planned re-analysis of data from the initial Phase III
     clinical trial of Omigard.   The company plans to announce details
     regarding the number of patients to be added to the trial, the
     anticipated financial impact, and other potential implications on the
     Omigard development program following the completion of discussions
     with FDA. If the FDA agrees with the company's plans to increase
     enrollment in this clinical trial, the company currently anticipates
     that enrollment will be completed in mid-2008.

Conference Call and Webcast Tomorrow at 8:30 a.m. Eastern Time/5:30 a.m. Pacific Time

Cadence management will host a conference call on Tuesday, May 15, 2007 at 8:30 a.m. Eastern Time (5:30 a.m. Pacific Time) to discuss financial results for the first quarter ended March 31, 2007. Interested investors may participate in the conference call by dialing 800-289-0572 (domestic) or 913-981-5543 (international). To access the webcast, please log on to the company's website at http://www.cadencepharm.com/ and go to the Investor Relations page. A replay of the webcast will be available approximately two hours after the call and remain available on the company's website until the next earnings call.

About Cadence Pharmaceuticals, Inc.

Cadence Pharmaceuticals is a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting. The company currently has two Phase III products in development, IV APAP (acetaminophen for injection) for the treatment of acute pain and fever, and Omigard (omiganan pentahydrochloride 1% aqueous gel) for the prevention of catheter-related infections. For more information about Cadence's pipeline, visit http://www.cadencepharm.com/.

Forward-Looking Statements

Cadence cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements. The inclusion of forward-looking statements should not be regarded as a representation by Cadence that any of its plans will be achieved. Actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in Cadence's business, including, without limitation: the progress and results of the company's clinical trials of IV APAP and Omigard, including any delays in commencing or completing enrollment; unexpected adverse side effects or inadequate therapeutic efficacy of IV APAP or Omigard that could delay or prevent regulatory approval or commercialization, or that could result in recalls or product liability claims; the potential that FDA may not agree with the company's proposal to increase patient enrollment in the ongoing Phase III clinical trial of Omigard, or that discussions with FDA may delay the proposed increase in patient enrollment, or that FDA may apply a statistical penalty to this clinical trial; the results of the company's continuing re-analysis of the data provided by its licensor concerning the earlier Phase III clinical trial of Omigard; other difficulties or delays in development, testing, manufacturing and marketing of and obtaining regulatory approval for IV APAP or Omigard; the scope and validity of patent protection for IV APAP or Omigard; the company's ability to maintain patent protection for its product candidates and to commercialize its product candidates without infringing the patent rights of others; the market potential for pain, fever, local catheter site infections and other target markets, and its ability to compete; the potential to attract a strategic collaborator and terms of any related transaction; the company's ability to raise sufficient capital; and other risks detailed in Cadence's prior press releases as well as in Cadence's periodic public filings with the Securities and Exchange Commission.

You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and Cadence undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995.

Cadence(TM) and Omigard(TM) are trademarks of Cadence Pharmaceuticals, Inc.

  Contacts:  William R. LaRue                   Susan Neath
             SVP & Chief Financial Officer      Media & Investor Relations
             Cadence Pharmaceuticals, Inc.      Porter Novelli Life Sciences
             858-436-1400                       619-849-6007



                      CADENCE PHARMACEUTICALS, INC.
                      (a development stage company)
                    CONDENSED STATEMENTS OF OPERATIONS
                               (unaudited)

                                                    Three Months Ended
                                                         March 31,
                                                  2007               2006
  Operating expenses:
     Research and development                 $8,241,804        $28,735,246
     Marketing                                   302,183             95,758
     General and administrative                1,827,592            537,349
  Total operating expenses                    10,371,579         29,368,353

  Loss from operations                       (10,371,579)       (29,368,353)

  Other income, net                              811,881            127,273
  Net loss                                   $(9,559,698)      $(29,241,080)

  Basic and diluted net loss per share            $(0.34)           $(23.84)

  Shares used to compute basic and
   diluted net loss per share                 28,402,352          1,226,682



                      CADENCE PHARMACEUTICALS, INC.
                      (a development stage company)
                         CONDENSED BALANCE SHEETS

                                               March 31,       December 31,
                                                 2007              2006
                                              (unaudited)
                 Assets
  Current assets:
      Cash and cash equivalents              $77,442,626       $86,825,526
      Prepaid expenses and other current
       assets                                  1,177,718         1,168,160
  Total current assets                        78,620,344        87,993,686

  Property and equipment, net                  4,309,501         3,558,618
  Restricted cash                              2,867,281         1,233,281
  Other assets                                   608,521           536,042
  Total assets                               $86,405,647       $93,321,627

      Liabilities and Stockholders' Equity
  Current liabilities:
      Accounts payable                        $3,226,431        $2,073,726
      Accrued liabilities                      8,489,538         7,378,750
      Current portion of long-term debt        2,612,168         2,338,010
  Total current liabilities                   14,328,137        11,790,486

  Deferred rent                                1,403,589         1,460,109
  Long-term debt, less current portion         3,980,733         4,661,990
  Other long-term liabilities                     22,048                --
  Total stockholders' equity                  66,671,140        75,409,042
  Total liabilities and stockholders'
   equity                                    $86,405,647       $93,321,627